Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 13, 2021 10:28 ET | Source: Adhera Therapeutics, Inc.

Adhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes Drugs

Baton Rouge, LA, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today provides shareholders an...
June 07, 2021 08:45 ET | Source: Adhera Therapeutics, Inc.

Adhera Therapeutics Signs Letter of Intent with Melior Pharmaceuticals II to Acquire a New Class of Drug for Parkinson’s Disease

Adhera to acquire and develop MLR-1019 (armesocarb), the API in mesocarb – a drug previously sold in Europe for 37 years – for Parkinson’s DiseaseMLR-1019, a Phase 2-ready product, could have...
April 23, 2021 09:00 ET | Source: Adhera Therapeutics, Inc.

Adhera Therapeutics Appoints Trond K. Waerness to Board of Directors

Baton Rouge, LA, April 23, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera Therapeutics" or the "Company"), a clinical stage biopharmaceutical company engaged in the...
September 26, 2019 16:19 ET | Source: Adhera Therapeutics, Inc.

Adhera Therapeutics Announces Termination of Tender Offer for Preferred Stock

RESEARCH TRIANGLE PARK, NC, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and...
July 02, 2019 16:15 ET | Source: Adhera Therapeutics, Inc.

Adhera Therapeutics Announces Termination of Tender Offer for Warrants

RESEARCH TRIANGLE PARK, NC, July 02, 2019 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and...
April 04, 2019 09:15 ET | Source: Adhera Therapeutics, Inc.

Adhera Therapeutics Appoints Nancy Phelan as Chief Executive Officer

RESEARCH TRIANGLE PARK, NC, April 04, 2019 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and...
November 20, 2018 19:08 ET | Source: Adhera Therapeutics, Inc.

Adhera Therapeutics Provides Third Quarter 2018 Financial Results and Business Update

Research Triangle Park, NC, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX), an emerging specialty pharmaceutical company commercializing therapies that leverage its...
October 09, 2018 08:00 ET | Source: Marina Biotech, Inc.

Marina Biotech Announces Name Change to Adhera Therapeutics to More Closely Reflect the Mission of Improving Patient Outcomes

Research Triangle Park, NC, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a commercial stage pharmaceutical company focused on the development and commercialization of...